

## Special Issue

# Neutralizing Antibodies against SARS-CoV-2 and HIV

### Message from the Guest Editor

This Special Issue of *Vaccines* includes a collection of reviews and research articles that focus on neutralizing antibodies (NABs) against SARS-CoV-2 and HIV viruses, covering topics such as the cellular and molecular mechanisms of antibody-mediated antiviral activities, analyses of the antibodies' epitopes on viral antigens, structural bases of the antibody-antigen interactions, as well as implications of therapeutic developments. Our Special Issue aims to provide opinions/commentaries, summaries, and in-depth analyses of neutralizing antibodies against SARS-CoV-2 and HIV-1. In this Special Issue, research areas may include but are not limited to:

- Molecular mechanisms of antigen-antibody interactions of neutralizing, as well as certain non-neutralizing, antibodies against SARS-CoV-2 or HIV-1;
- Analyses of antibody epitopes on SARS-CoV-2 S or HIV-1 Env antigens;
- Current progress and limitations of antibody-based therapeutic development;
- Current progress and limitations of Nabs structure-based immunogen design;
- Your proposed topics that you believe would be potentially interesting to our community.

We look forward to receiving your contributions.

---

### Guest Editor

Dr. Zhi Yang

Department of Cell and Molecular Biology, University of California, Berkeley, CA, USA

---

### Deadline for manuscript submissions

closed (1 August 2024)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/151104](https://mdpi.com/si/151104)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).